Do paraneoplastic changes in diffuse FDG organ uptake predict relapse? - Wait for confirmation study : Reply to Jorgov et al. Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1220--30

Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):170-171. doi: 10.1007/s00259-016-3534-y.

Authors

Regine Kluge¹, Lars Kurch², Thomas Georgi², Dirk Hasenclever³

Affiliations

¹ Department of Nuclear Medicine, University Hospital of Leipzig, Liebigstraße 18, 04109, Leipzig, Germany. regine.kluge@medizin.uni-leipzig.de.
² Department of Nuclear Medicine, University Hospital of Leipzig, Liebigstraße 18, 04109, Leipzig, Germany.
³ Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Härtelstraße 16-18, 04107, Leipzig, Germany.

PMID: 27761620
DOI: 10.1007/s00259-016-3534-y

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Child
Fluorodeoxyglucose F18 / pharmacokinetics*
Hodgkin Disease / diagnostic imaging*
Hodgkin Disease / metabolism*
Humans
Neoplasm Recurrence, Local / diagnostic imaging*
Neoplasm Recurrence, Local / metabolism
Paraneoplastic Syndromes / diagnostic imaging*
Paraneoplastic Syndromes / metabolism*
Positron Emission Tomography Computed Tomography / methods
Positron-Emission Tomography / methods
Prognosis
Risk Assessment / methods

Substances

Fluorodeoxyglucose F18